The evolution of therapeutic modalities drives the adoption of single-use technologies.
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
Recent recalls have contributed to the pharmaceutical industry?s heightened awareness of glass delamination (i.e., the formation of glass flakes in a vial), which could affect drug quality and patient safety. To confront this growing problem effectively, drugmakers must understand its causes.
PharmTech's monthly newsletter, Equipment and Processing Report, reviews the Editor's Picks for the October 2011 edition from Edwards and Moyno.
The future, and increasingly the present, for aseptic operations is isolated robotics. Companies that wish to gain competitive advantages in their operations are stepping up and taking notice.
EMA released two concept papers for consultation that address the need to revise existing guidelines on biosimilar medicines and influenza vaccines.
John Kelly, vice-president of strategy and transitioning sites for Pfizer Global Supply, discusses the company's manufacturing and supply strategy and network.
Europe establishes new collaborative system to track products.
AAPS Global Health Focus Group's Kishor M. Wasan discusses new initiatives.
Single-use components in the fill–finish line provides increased flexibility to multiproduct manufacturers.
Drugmakers and packagers are pursuing various initiatives to reduce their carbon footprints. This article contains bonus material.
Getting the most value out of M&As requires proper upfront legwork.
Corporate management must be held accountable for quality at all levels.
The authors examine risk management relating to the quality issues of clinical-trial materials and discuss areas that would benefit from additional consideration and harmonization.
Could oral absorption-enhancing technologies change the shape of protein delivery?
The authors describe the concept of the limiting discriminatory the limiting discriminatory threshold (LDT) as an objective means of evaluating the inherent quality requirement of a large-sample content-uniformity test.
The authors summarize a recent FDA–PQRI workshop on process drift.
A Q&A with Rao Tatapudy, vice-president of scientific affairs at Catalent, on recent industry trends.
Letting contamination build up can cause multiple headaches.
In an effort to balance bilateral trade, India is urging China to increase Indian pharmaceutical imports.
New product reviews for October 2011 focusing on analytical instrumentation.
Manufacturers fund research and reduce prices to tackle diseases.
The global excipients market shows moderate growth, increased consolidation, and expansion activity in emerging markets and select product areas.
Despite new hurdles, industry must move forward and fulfill its mission.
This risk-management case study focuses on assessing empty capsules.
In a quick-fire interview, Dr Stephen Taylor, Vice President & Commercial Director at Fujifilm Diosynth Biotechnologies, looks at some of the challenges facing biologics outsourcing.
GlaxoSmithKline (GSK) is looking to racecar technology as it seeks to improve its manufacturing, R&D, and consumer-healthcare areas. The company has formed a long-term partnership with the UK-based McLaren Group, which is best known for its expertise in the Formula 1 motor sport.
